DeLand, Florida— March 4, 2010 — Avail Clinical Research, a privately owned research facility, founded in 1998 in DeLand, Florida, announces the launch of several smoking cessation clinical trials to test investigational treatment options for those already diagnosed with a nicotine addiction. “We are very pleased to begin the systemic evaluation of our smoking cessation research studies to help find a viable investigational treatment solution to those suffering from nicotine addiction,” said Bruce G. Rankin, DO, CPI., the Vice Chief of Medicine at Florida Hospital DeLand. “We believe that these research studies will build significantly on the data generated by other studies conducted on investigational treatment options for nicotine addiction.” Dr. Rankin has been conducting research with Avail Clinical Research since 1999 and is currently the Medical Director.

The smoking cessation research studies will enroll those already diagnosed with nicotine addiction, which includes symptoms like intense cravings for a cigarette when stressed, and anxiety, agitation, headaches, and nausea when without a cigarette for more than thirty minutes. In order to participate in the studies volunteers must be diagnosed with nicotine addiction. Avail Clinical Research will not take volunteers who:

• have any evidence or treatment of malignancy within the previous 5 years,
• have a history of alcohol or substance abuse within the previous 5 years,
• have used an investigatory drug or participated in an investigatory study within 30 days of the screening,
• are pregnant, or
• are breast-feeding.

Avail Clinical Research will provide participants with study related care, including physical examinations, laboratory services and study medications. Participants will also be compensated for time and travel. For more information regarding participation in our clinical trials, contact Avail Clinical Research at 386.310.1334, or at www.AvailClinical.com.